Back to top
more

OPKO Health (OPK)

(Real Time Quote from BATS)

$1.28 USD

1.28
1,840,640

+0.02 (1.59%)

Updated Aug 6, 2025 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

Zacks Equity Research

HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

Zacks Equity Research

OPKO Health's BioReference Laboratories Introduces NGS Assay

by Zacks Equity Research

OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.

Zacks Equity Research

Baxter (BAX) Attains FDA De Novo Authorization for Theranova

by Zacks Equity Research

Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.

Zacks Equity Research

Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

by Zacks Equity Research

Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

Zacks Equity Research

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects

Benjamin Rains headshot

Learn How to Find Strong, Cheap Stocks Under $10 with this Screener

by Benjamin Rains

We screened for a niche within the market that is attractive to many: strong, "cheap" stocks that are currently trading for under $10 a share...

Zacks Equity Research

Why Is OPKO Health (OPK) Down 43.5% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems' (VEEV) core Subscription business segment performs impressively in Q2.

Zacks Equity Research

Smith+Nephew Unveils Digital Platform to Boost Patient Care

by Zacks Equity Research

With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.

Zacks Equity Research

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings in Your Portfolio

by Zacks Equity Research

Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.

Zacks Equity Research

The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed

by Zacks Equity Research

The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed

Zacks Equity Research

Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (OPK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Thermo Fisher Unveils Suite of Hematology-Oncology Solutions

by Zacks Equity Research

The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.

Zacks Equity Research

Masimo Releases Favorable Study Results on Pulse Oximetry

by Zacks Equity Research

The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.

Urmimala Biswas headshot

MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential

by Urmimala Biswas

MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.

Zacks Equity Research

Why Hold Strategy is Apt for Varian Medical (VAR) Stock Now

by Zacks Equity Research

Investor confidence is high in Varian Medical (VAR) stock at the moment.

Zacks Equity Research

Here's Why You Should Add NextGen Stock to Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

Zacks Equity Research

PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol

by Zacks Equity Research

PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.

Zacks Equity Research

PerkinElmer Launches Workstations for Coronavirus Testing

by Zacks Equity Research

PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.

Zacks Equity Research

Do Options Traders Know Something About OPKO Health (OPK) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Zacks Equity Research

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

by Zacks Equity Research

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

Zacks Equity Research

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

by Zacks Equity Research

Accuray (ARAY) registered decline in Product and Service revenues in Q4